Treatment of Actinic Keratosis With 5% KOH Solution

Prospective, Single-arm, Medical Device Investigation According to § 23b MPG [German Medical Devices Act] on Efficacy and Safety of Treatment of Actinic Keratosis With a 5% Potassium Hydroxide Solution (AKOHDerm)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04024579

Acronym

TAKKOH

Enrollment

Registered

2019-07-18

Start date

2017-10-17

Completion date

2019-08-25

Last updated

2019-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic Keratoses

Brief summary

This is a prospective single-arm multicenter medical device study to investigate the clinical efficacy and safety of the treatment of actinic keratosis with a 5% potassium hydroxide solution. In total, 68 patients with actinic keratosis grade I/II, who meet all inclusion criteria and do not meet none of the exclusion criteria are to be enrolled and topically treated twice daily for up to 3 cycles of 14 days of treatment followed by 14 non-treatment days. The primary objective is treatment success at the individual end-of-treatment visit of all AK lesions present at baseline and treated with the investigational product. Beside this, adverse events will be collected at each visit and evaluated in order to investigate clinical safety.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * Age: 30 to 80 years * Adults with AK grade I (mild) or II (moderate)

Exclusion criteria

* Number of lesions requiring treatment \> 10 * Lesion to be treated \> 20 mm (maximum diameter) * Lesions directly adjoining to the eyes, eyelids, nostrils, mouth or mucosal tissue, * Need for topical treatment of a cancerous area * Presence of a relapsing, persistent, indurated, thickened, painful, bleeding, ulcerated and/or rapidly growing lesion * Presence of a persistent or relapsing lesion despite appropriate treatment with AKOHDerm or another appropriate treatment * High risk of progression of AK according as assessed by a medical doctor * Pharmacological or physical local therapy of AK in the area foreseen for treatment dur-ing the last 12 weeks * Treatment with systemic corticosteroids during the last 2 weeks * Planned concomitant treatment of the same AK lesions during the study in addition to study treatment * Other skin diseases in the area of application which might interfere with clinical signs * Known predisposition for hypertrophic scarring / keloidosis * Primary or secondary immunodeficiency * Treatment with interferons, interferon inducers or immunomodulators during the last 4 weeks * Pregnancy and lactation * No reliable contraception in women of child-bearing potential * Other serious diseases which are according to the investigator in conflict with the par-ticipation * Obvious unreliability or lack of cooperation - known addiction to alcohol, medicinal products or drugs * Dependent relationship with sponsor or investigator * Participation in a clinical trial within the last 30 days * Previous participation in this study

Design outcomes

Primary

Measure	Time frame	Description
Efficacy (Patients with treatment success): defined as dermatoscopically confirmed complete remission of all AK lesions by the investigator	Visit 14 days after EOT (End of treatment); up to 12 weeks depending treatment cycles nessesary	Treatment success (yes, no) at the individual end-of-treatment visit (VE), defined as dermatoscopically confirmed complete remission of all AK lesions by the investigator, which were present at V0 and treated with the investigational product (complete clearance).

Countries

Germany

Outcome results